What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
The scientist’s investigation covers issues in Melanoma, Cancer, Surgery, Internal medicine and Immunology.
His Melanoma research is multidisciplinary, incorporating perspectives in Sentinel lymph node, Ipilimumab, Radiology and Lymph node.
His biological study spans a wide range of topics, including Cancer research, Clinical trial, Bioinformatics, Disease and Stage.
His Surgery research integrates issues from Lymphadenectomy, Metastasis and Alpha interferon.
His Internal medicine research incorporates themes from Gastroenterology and Oncology.
His study in the fields of Adjuvant under the domain of Oncology overlaps with other disciplines such as In patient.
His most cited work include:
- Final Version of 2009 AJCC Melanoma Staging and Classification (3479 citations)
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (1593 citations)
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (1593 citations)
What are the main themes of his work throughout his whole career to date?
Alexander M.M. Eggermont mainly focuses on Melanoma, Internal medicine, Oncology, Surgery and Cancer.
His work carried out in the field of Melanoma brings together such families of science as Immunology, Lymph node, Metastasis, Radiology and Sentinel node.
His Internal medicine study frequently links to adjacent areas such as Gastroenterology.
His study looks at the relationship between Oncology and topics such as Ipilimumab, which overlap with Nivolumab.
He has included themes like Clinical trial and Bioinformatics in his Cancer study.
His work in Melphalan addresses subjects such as Tumor necrosis factor alpha, which are connected to disciplines such as Pathology and Cytokine.
He most often published in these fields:
- Melanoma (48.92%)
- Internal medicine (39.14%)
- Oncology (30.50%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (39.14%)
- Oncology (30.50%)
- Melanoma (48.92%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Melanoma, Cancer and Adjuvant therapy.
The concepts of his Oncology study are interwoven with issues in MEDLINE, Randomized controlled trial, Confidence interval, Metastasis and Immunotherapy.
In the field of Immunotherapy, his study on PD-L1 overlaps with subjects such as CCR9.
Alexander M.M. Eggermont is studying Cutaneous melanoma, which is a component of Melanoma.
His work deals with themes such as Guideline, Translational research, Quality of life and Outcomes research, which intersect with Cancer.
He has researched Adjuvant therapy in several fields, including Gastroenterology, Breslow Thickness and Cohort.
Between 2017 and 2021, his most popular works were:
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (1593 citations)
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (1593 citations)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (659 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Cancer, Oncology, Melanoma and Immunotherapy are his primary areas of study.
His studies in Cancer integrate themes in fields like Apoptosis, Guideline, Clinical trial and Immune system.
His Oncology research includes themes of Clinical research, Chemotherapy, Neoplasms therapy, Metastasis and Stage.
His Melanoma research incorporates elements of PD-L1, Drug resistance and Lymph node.
Alexander M.M. Eggermont interconnects Blockade, Messenger RNA and Cancer research in the investigation of issues within Immunotherapy.
His Blockade study incorporates themes from Antibiotics, Antibody, Immunology and Akkermansia muciniphila.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
